

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Point-of-care creatinine tests to assess kidney function before administering intravenous contrast for computed tomography (CT) imaging

Stakeholder list

<p>Manufacturers</p> <p>Abaxis now part of Zoetis Abbott Diagnostics – Point of Care Division Fujifilm UK Limited Nova Biomedical Radiometer Ltd Siemens Healthcare Limited</p>
<p>Professional groups</p> <p>Association for Clinical Biochemistry and Laboratory Medicine British Renal Society British Society of Interventional Radiology Institute of Biomedical Science Renal Association Royal College of Physicians Royal College of Radiologists The Society and College of Radiographers</p>
<p>Patient/carer groups</p> <p>Kidney Care UK Kidney Research UK Polycystic Kidney Disease Charity</p>
<p>External Assessment Group</p> <p>Centre for Reviews and Dissemination and Centre for Health Economics, University of York</p>
<p>Others</p> <p>Department of Health and Social Care Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency NHS England Welsh Government</p>
<p>Specialist Committee Members</p>

Definitions:Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).